187 related articles for article (PubMed ID: 34752601)
1. Microlyse: a thrombolytic agent that targets VWF for clearance of microvascular thrombosis.
de Maat S; Clark CC; Barendrecht AD; Smits S; van Kleef ND; El Otmani H; Waning M; van Moorsel M; Szardenings M; Delaroque N; Vercruysse K; Urbanus RT; Sebastian S; Lenting PJ; Hagemeyer CE; Renné T; Vanhoorelbeke K; Tersteeg C; Maas C
Blood; 2022 Jan; 139(4):597-607. PubMed ID: 34752601
[TBL] [Abstract][Full Text] [Related]
2. Plasmin cleavage of von Willebrand factor as an emergency bypass for ADAMTS13 deficiency in thrombotic microangiopathy.
Tersteeg C; de Maat S; De Meyer SF; Smeets MW; Barendrecht AD; Roest M; Pasterkamp G; Fijnheer R; Vanhoorelbeke K; de Groot PG; Maas C
Circulation; 2014 Mar; 129(12):1320-31. PubMed ID: 24449821
[TBL] [Abstract][Full Text] [Related]
3. Plasmin-cleaved von Willebrand factor as a biomarker for microvascular thrombosis.
El Otmani H; Frunt R; Smits S; Barendrecht AD; de Maat S; Fijnheer R; Lenting PJ; Tersteeg C
Blood; 2024 May; 143(20):2089-2098. PubMed ID: 38271661
[TBL] [Abstract][Full Text] [Related]
4. VWF excess and ADAMTS13 deficiency: a unifying pathomechanism linking inflammation to thrombosis in DIC, malaria, and TTP.
Schwameis M; Schörgenhofer C; Assinger A; Steiner MM; Jilma B
Thromb Haemost; 2015 Apr; 113(4):708-18. PubMed ID: 25503977
[TBL] [Abstract][Full Text] [Related]
5. Amplified endogenous plasmin activity resolves acute thrombotic thrombocytopenic purpura in mice.
Tersteeg C; Joly BS; Gils A; Lijnen R; Deckmyn H; Declerck PJ; Plaimauer B; Coppo P; Veyradier A; Maas C; De Meyer SF; Vanhoorelbeke K
J Thromb Haemost; 2017 Dec; 15(12):2432-2442. PubMed ID: 28981198
[TBL] [Abstract][Full Text] [Related]
6. Formation and Resolution of Pial Microvascular Thrombosis in a Mouse Model of Thrombotic Thrombocytopenic Purpura.
Adili R; Holinstat M
Arterioscler Thromb Vasc Biol; 2019 Sep; 39(9):1817-1830. PubMed ID: 31340669
[TBL] [Abstract][Full Text] [Related]
7. Thrombotic thrombocytopenic purpura and anti-thrombotic therapy targeted to von Willebrand factor.
Zhou Z; Dong JF
Curr Vasc Pharmacol; 2012 Nov; 10(6):762-6. PubMed ID: 22022775
[TBL] [Abstract][Full Text] [Related]
8. Expression of a structurally constrained von Willebrand factor variant triggers acute thrombotic thrombocytopenic purpura in mice.
Morioka Y; Casari C; Wohner N; Cho S; Kurata S; Kitano A; Christophe OD; Lenting PJ; Li R; Denis CV; Prévost N
Blood; 2014 May; 123(21):3344-53. PubMed ID: 24713928
[TBL] [Abstract][Full Text] [Related]
9. Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura.
Scully M; Cataland SR; Peyvandi F; Coppo P; Knöbl P; Kremer Hovinga JA; Metjian A; de la Rubia J; Pavenski K; Callewaert F; Biswas D; De Winter H; Zeldin RK;
N Engl J Med; 2019 Jan; 380(4):335-346. PubMed ID: 30625070
[TBL] [Abstract][Full Text] [Related]
10. Caplacizumab: an anti-von Willebrand factor antibody for the treatment of thrombotic thrombocytopenic purpura.
Hollifield AL; Arnall JR; Moore DC
Am J Health Syst Pharm; 2020 Jul; 77(15):1201-1207. PubMed ID: 32588878
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of von Willebrand factor-platelet glycoprotein Ib interaction prevents and reverses symptoms of acute acquired thrombotic thrombocytopenic purpura in baboons.
Feys HB; Roodt J; Vandeputte N; Pareyn I; Mottl H; Hou S; Lamprecht S; Van Rensburg WJ; Deckmyn H; Vanhoorelbeke K
Blood; 2012 Oct; 120(17):3611-4. PubMed ID: 22855603
[TBL] [Abstract][Full Text] [Related]
12.
Tersteeg C; Roodt J; Van Rensburg WJ; Dekimpe C; Vandeputte N; Pareyn I; Vandenbulcke A; Plaimauer B; Lamprecht S; Deckmyn H; Lopez JA; De Meyer SF; Vanhoorelbeke K
Blood; 2017 Feb; 129(8):1030-1038. PubMed ID: 28011677
[TBL] [Abstract][Full Text] [Related]
13. VWF-targeted thrombolysis to overcome rh-tPA resistance in experimental murine ischemic stroke models.
van Moorsel MVA; de Maat S; Vercruysse K; van Leeuwen EM; Jacqmarcq C; Bonnard T; Vivien D; van der Worp HB; Dijkhuizen RM; Maas C
Blood; 2022 Dec; 140(26):2844-2848. PubMed ID: 35960811
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in thrombotic thrombocytopenic purpura.
Sadler JE; Moake JL; Miyata T; George JN
Hematology Am Soc Hematol Educ Program; 2004; ():407-23. PubMed ID: 15561695
[TBL] [Abstract][Full Text] [Related]
15. New Therapeutic Targets and Treatment Options for Thrombotic Microangiopathy: Caplacizumab and Ravulizumab.
Chung C
Ann Pharmacother; 2021 Mar; 55(3):330-343. PubMed ID: 32715723
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of efficacy and safety of the anti-VWF Nanobody ALX-0681 in a preclinical baboon model of acquired thrombotic thrombocytopenic purpura.
Callewaert F; Roodt J; Ulrichts H; Stohr T; van Rensburg WJ; Lamprecht S; Rossenu S; Priem S; Willems W; Holz JB
Blood; 2012 Oct; 120(17):3603-10. PubMed ID: 22948047
[TBL] [Abstract][Full Text] [Related]
17. Von Willebrand factor assays in patients with acquired immune thrombotic thrombocytopenia purpura treated with caplacizumab.
Bowyer A; Brown P; Hopkins B; Scully M; Shepherd F; Lowe A; Mensah P; Maclean R; Kitchen S; van Veen JJ
Br J Haematol; 2022 May; 197(3):349-358. PubMed ID: 35262910
[TBL] [Abstract][Full Text] [Related]
18. N-acetylcysteine reduces the size and activity of von Willebrand factor in human plasma and mice.
Chen J; Reheman A; Gushiken FC; Nolasco L; Fu X; Moake JL; Ni H; López JA
J Clin Invest; 2011 Feb; 121(2):593-603. PubMed ID: 21266777
[TBL] [Abstract][Full Text] [Related]
19. Molecular basis of ADAMTS13 dysfunction in thrombotic thrombocytopenic purpura.
Manea M; Karpman D
Pediatr Nephrol; 2009 Mar; 24(3):447-58. PubMed ID: 18807073
[TBL] [Abstract][Full Text] [Related]
20. Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura.
Peyvandi F; Scully M; Kremer Hovinga JA; Cataland S; Knöbl P; Wu H; Artoni A; Westwood JP; Mansouri Taleghani M; Jilma B; Callewaert F; Ulrichts H; Duby C; Tersago D;
N Engl J Med; 2016 Feb; 374(6):511-22. PubMed ID: 26863353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
